MMP9 and sarcopenia: Empagliflozin, a sodium-glucose co-transporter 2 inhibitor, may inhibit sarcopenia-induced skeletal muscle fibrosis and improve skeletal muscle function through the AMPKα/MMP-9/TGF-β1/Smad pathway (59).